Hyperspectral imaging (HSI), a widely used biosensing technique, has been applied to tumor detection. Rapid, accurate, and low-cost detection of blood cancer using hyperspectral technology remains a challenge. We developed a new method to discriminate blood cancer using hyperspectral imaging (HSI) and the forward searching method (FSM). Four commonly used classification models are applied for four types of blood cancer spectra recognition. The support vector machine (SVM) model with the highest recognition accuracy (94.5%) combined with HSI achieves high-precision tumor identification. For higher recognition accuracy and lower hardware barriers, based on the selection probabilities of spectral lines calculated by a multi-objective atomic orbital search method, the FSM is proposed for HSI feature selection. With the proposed method, the wavelength band range of the spectrum is reduced by at least 50%. Compared with the traditional dimensionality reduction methods, the FSM can obtain a higher accuracy rate with lower hardware requirements. These results show that our proposed method can achieve non-invasive rapid screening of blood cancers with lower hardware requirements. Therefore, HSI assisted with FSM and SVM hybrid models can be a powerful and promising tool for blood cancer detection.

Download full-text PDF

Source
http://dx.doi.org/10.1039/d3ay00787aDOI Listing

Publication Analysis

Top Keywords

blood cancer
20
hyperspectral imaging
12
lower hardware
12
forward searching
8
searching method
8
imaging hsi
8
cancer hyperspectral
8
method fsm
8
recognition accuracy
8
proposed method
8

Similar Publications

ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells.

Cytotherapy

January 2025

Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Electronic address:

The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval.

View Article and Find Full Text PDF

Introduction: Prostate cancer (PCa) is the commonest urologic cancer worldwide and the leading cause of male cancer deaths in Nigeria. In Nigeria, orchidectomy remains the primary androgen deprivation therapy. Dihydrotestosterone (DHT) is the active prostatic androgen, but its relationship with PCa severity has not been extensively studied in Africa.

View Article and Find Full Text PDF

GITRL enhances cytotoxicity and persistence of CAR-T cells in cancer therapy.

Mol Ther

January 2025

Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai, China, 200241. Electronic address:

CAR T-cell therapy has achieved remarkable clinical success in treating hematological malignancies. However, its clinical efficacy in solid tumors is less satisfactory, partially due to poor in vivo expansion and limited persistence of CAR-T cells. Here, we demonstrated that the overexpression of glucocorticoid-induced tumor necrosis factor receptor-related protein ligand (GITRL) enhances the anti-tumor activity of CAR-T cells.

View Article and Find Full Text PDF

One hallmark of cancer is the upregulation and dependency on glucose metabolism to fuel macromolecule biosynthesis and rapid proliferation. Despite significant pre-clinical effort to exploit this pathway, additional mechanistic insights are necessary to prioritize the diversity of metabolic adaptations upon acute loss of glucose metabolism. Here, we investigated a potent small molecule inhibitor to Class I glucose transporters, KL-11743, using glycolytic leukemia cell lines and patient-based model systems.

View Article and Find Full Text PDF

Blood-based epigenome-wide association study and prediction of alcohol consumption.

Clin Epigenetics

January 2025

Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.

Alcohol consumption is an important risk factor for multiple diseases. It is typically assessed via self-report, which is open to measurement error through recall bias. Instead, molecular data such as blood-based DNA methylation (DNAm) could be used to derive a more objective measure of alcohol consumption by incorporating information from cytosine-phosphate-guanine (CpG) sites known to be linked to the trait.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!